In a report released on October 7, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva, with a price target of €7.70. The company’s shares closed yesterday at €4.72.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Telliez is a 5-star analyst with an average return of 62.9% and a 54.72% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Abivax SA, and Valneva.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valneva with a €8.80 average price target.
0OB3 market cap is currently €836.3M and has a P/E ratio of -10.99.
Read More on GB:0OB3:
Disclaimer & DisclosureReport an Issue
- Valneva price target lowered to $13 from $14 at Guggenheim
- Valneva’s Earnings Call: Growth Amid Challenges
- Valneva’s Stock: A Buy Rating Amid Overreaction and Promising Vaccine Prospects
- Valneva selloff on FDA suspension overdone, says H.C. Wainwright
- Valneva price target lowered to $14 from $18 at Jefferies
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
/Salesforce%20Inc%20logo%20on%20building-by%20Sundry%20Photography%20via%20Shutterstock.jpg)